Matthew Gibbs, PharmD

home / authors / matthew-gibbs

Articles

Career paths illustration | Image credit: Sergey Nivens - stock.adobe.com

Op-Ed: Nontraditional Pharmacy Career Paths Continue to Gain Traction

Matthew Gibbs, PharmD
April 11th 2023

Pharmacy benefit managers offer mentorship, training opportunities, and professional advancement beyond what's available in traditional pharmacy careers.

Read More

Overwhelmed, Overburdened Pharmacists Spend Less Time With Patients, Hurting Retail Pharmacy Business

Overwhelmed, Overburdened Pharmacists Spend Less Time With Patients, Hurting Retail Pharmacy Business

Matthew Gibbs, PharmD
December 23rd 2021

The health of a pharmacy business is under attack from many directions, but retail pharmacies can take steps to alleviate some of this pressure to improve the health of their business.

Read More

Latest Updated Articles

Sweden - March 23, 2015: McDonald's yellow and red logo advertising sign placed on a pole with against clear blue sky
Published: October 23rd 2024 | Updated: October 24th 2024
What to Know About E Coli Outbreak Linked to McDonald’s Quarter Pounders
10 Pharmacy Quotes That Will Make You Rethink the Profession
Published: January 18th 2016 | Updated: October 18th 2024
10 Pharmacy Quotes That Will Make You Rethink the Profession
Gabapentin Differs From Pregabalin in Several Key Ways
Published: September 22nd 2015 | Updated: October 14th 2024
Gabapentin Differs From Pregabalin in Several Key Ways
The US Capitol building.
Published: August 30th 2024 | Updated: November 21st 2024
Congress Requests Corrections to Testimony From Three Largest Pharmacy Benefit Manager Executives Following FTC Report
In this photo illustration, the Centers for Medicare and Medicaid Services (CMS) logo is displayed on a smartphone screen.
Published: October 8th 2024 | Updated: November 21st 2024
What Drug Rates Are Reported in Price Transparency Data?
Image Credit: Syda Productions - stock.adobe.com
Published: October 7th 2024 | Updated: November 21st 2024
What Went Wrong: How Formularies, Contracts, and Rebates Created a Headwind for Biosimilars